These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27182231)

  • 1. Gaucher disease in Iraqi children (Clinical, diagnostic & therapeutic aspects).
    Thejeal RF; Kadhum AJ
    Pak J Med Sci; 2016; 32(2):319-23. PubMed ID: 27182231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J; Szücs FZ; Benkö K; Maródi L
    Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
    Piran S; Roberts A; Patterson MA; Amato D
    Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R; Arndt S; Levin JB
    S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
    Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of enzyme replacement therapy in Turkish patients with Gaucher disease: does late intervention affect the response?
    Arikan-Ayyildiz Z; Yüce A; Emre S; Baysoy G; Saltik-Temizel IN; Gürakan F
    Turk J Pediatr; 2011; 53(5):499-507. PubMed ID: 22272449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
    Weinreb NJ; Charrow J; Andersson HC; Kaplan P; Kolodny EH; Mistry P; Pastores G; Rosenbloom BE; Scott CR; Wappner RS; Zimran A
    Am J Med; 2002 Aug; 113(2):112-9. PubMed ID: 12133749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cessation of enzyme replacement therapy in Gaucher disease.
    Grinzaid KA; Geller E; Hanna SL; Elsas LJ
    Genet Med; 2002; 4(6):427-33. PubMed ID: 12509713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of bone marrow response with hematological, biochemical, and visceral responses to enzyme replacement therapy of nonneuronopathic (type 1) Gaucher disease in 30 adult patients.
    Poll LW; Koch JA; Willers R; Aerts H; Scherer A; Häussinger D; Mödder U; vom Dahl S
    Blood Cells Mol Dis; 2002; 28(2):209-20. PubMed ID: 12064917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [French results of enzyme replacement therapy in Gaucher's disease].
    Schaison G; Caubel I; Belmatoug N; Billette de Villemeur T; Saudubray JM
    Bull Acad Natl Med; 2002; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics.
    Giraldo P; Pocoví M; Pérez-Calvo J; Rubio-Félix D; Giralt M
    Haematologica; 2000 Aug; 85(8):792-9. PubMed ID: 10942924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G; Ponce E; Basack N; Freigeiro D; Aversa L; Graciela E; Kohan R
    J Pediatr; 2007 Aug; 151(2):197-201. PubMed ID: 17643778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gaucher disease.
    Nagral A
    J Clin Exp Hepatol; 2014 Mar; 4(1):37-50. PubMed ID: 25755533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gaucher disease type 1: the first experience of enzyme replacement therapy in pediatric practice in Moldova - case report.
    Uşurelu N; Blăniţă D; Boiciuc C; Hlistun V; Egorov V; Popovici E; Gnatcova E; Stamati A; Oglindă A; Revenco N; Gladun S; Ţurea V
    Med Pharm Rep; 2021 Aug; 94(Suppl No 1):S57-S60. PubMed ID: 34527913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
    J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spectrum of abdominal sonographic findings in 103 pediatric patients with Gaucher disease.
    Patlas M; Hadas-Halpern I; Abrahamov A; Elstein D; Zimran A
    Eur Radiol; 2002 Feb; 12(2):397-400. PubMed ID: 11870441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achievement of therapeutic goals with low-dose imiglucerase in Gaucher disease: a single-center experience.
    Tukan I; Hadas-Halpern I; Altarescu G; Abrahamov A; Elstein D; Zimran A
    Adv Hematol; 2013; 2013():151506. PubMed ID: 24285960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat.
    Sidhu K; Boyd SK; Khan A
    Mol Genet Metab Rep; 2020 Sep; 24():100606. PubMed ID: 32509532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.